Tackling significant unmet needs in cancer and fibrosis

Amplia Therapeutics Limited is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Our most frequently asked question... Our service is free for investors, and we do not sell subscriptions. We search for small ASX-listed companies and profile the ones we think may have investment potential. Fortunately, some companies we profile see the value in attracting new investors and engage us to boost the visibility of their profiles - these are marked "promoted" for transparency. This allows us to maintain this website and continue doing what we love without asking you to foot the bill. Thank you for visiting and if you have any questions please do not hesitate to ask.

Company

Amplia Therapeutics Ltd
Website

ampliatx.com
Sector

Biotechnology
Industry

Biotechnology

Code

ASX:ATX
Socials

Company Overview

Promoted

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Share this profile:

The Right Assets, The Right People And The Right Investors At The Right Time.

Amplia's technology is addressing a multi-billion-dollar market by targeting fibrotic cancer & chronic fibrotic diseases.

Investors

Platinum Investment Management and BlueFlag Holdings (an investment vehicle of former Macquarie Group CEO Allan Moss), are recent cornerstone investors in Amplia.

Timing & Expertise

The Amplia team have significant experience commercialising drugs and have recently appointed Nucleus Network to conduct its Phase 1 clinical trials.

Unmet Need

Amplia's technology has been validated by the U.S. FDA by being awarded two Orphan Drug Designations for IPF and Pancreatic Cancer.

ASX presentation

Click here to view the latest presentation

View Here

The right opportunity...

Amplia are among the first in the world to explore how FAK could expand the growing multi-billion-dollar checkpoint inhibitor market. The global immune checkpoint inhibitors market was valued at $10,566 million in 2017, and is projected to reach $56,530 million by 2025, registering a CAGR of 20.1% from 2018 to 2025. (Source: Allied Market Research). Historical growth in this market has also been significant (see image).

...being tackled by the right assets...

Amplia's AMP886 and AMP945 are targeting several conditions within both Cancer and Fibrosis, which gives them an opportunity to take 'multiple shots at goal'. Furthermore, early studies have demonstrated that Amplia's molecules are highly differentiated and competitive. AMP945 in particular is believed to be highly focused in what it targets, which could suggest improved safety characteristics in comparison to other FAK assets currently being developed.

...being managed by the right people...

The Amplia board have a significant track record in the development and commercialisation of drugs. A comprehensive list of achievements can be found here, and includes but is not limited to multi-billion-dollar transactions to big-pharma in the U.S. In addition, Amplia's Scientific Advisory Board consists of world leaders in FAK biology, including recent appointment Professor Paul Timpson.

Warwick Tong MB ChB MPP GAICD

Non-Executive Chairman

John Lambert PhD GAICD

Chief Executive Officer & Managing Director

Robert Peach PhD

Independent Non-Executive Director

Christopher Burns BSc (Hons) PhD GAICD

Non-Executive Director

....and supported by the right investors...

Platinum Investment Management has participated in Amplia's two most recent capital raises and have became a significant cornerstone investor in Amplia. In addition, BlueFlag Holdings Pty Ltd ("BlueFlag") has also became a substantial holder as a result of the most recent capital raise. BlueFlag is an investment vehicle of Allan Moss who is the former CEO of Macquarie Group Ltd (ASX:MQG) and is widely regarded to be a sophisticated biotechnology investor.

Substantial Shareholder

Click here to view BlueFlag Holdings Pty Ltd Substantial Shareholder Notice.

View Here

... at the right time.

Amplia has multiple value accretive milestones mapped out over the next 18 months and is fully funded to execute on its growth plans. After receiving positive results from its pre-clinical toxicology studies for AMP945 Amplia have appointed Nucleus Network to conduct its Phase 1 clinical trial testing. Amplia have also recently been awarded Orphan Drug Designation by the FDA for Idiopathic Pulmonary Fibrosis (IPF) and Pancreatic Cancer bringing further validation to Amplia's technology.

Information current at 24 July 2020

This section contains information provided by Amplia Therapeutics Ltd, with the exception of any sections labeled as "risks". Although all due care has been taken, Mawson Graham ("SmallCapInsider") does not warrant the accuracy of the information provided in this section. It is not intended as an offer, invitation solicitation or recommendation with respect to the purchase or sale of any securities. The above information should not be relied upon as the sole representation of any matter that a potential investor should consider in evaluating Amplia Therapeutics Ltd. Its affiliates or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to or endorsement of, the accuracy or completeness of any information, statements, representations or forecasts contained above, and they do not accept any liability for any statement made in, or omitted from, the above. Prospective investors should make their own independent evaluation of an investment in Amplia Therapeutics Ltd. This information may contain forward looking statements concerning Amplia Therapeutics Ltd. Forward-looking statements are not statements of historical fact and actual events and results may differ materially from those described in the forward looking statements as a result of a variety of risks, uncertainties and other factors. Forward-looking statements are inherently subject to business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in any forward-looking information provided by Amplia Therapeutics Ltd, or on behalf of Amplia Therapeutics Ltd. Forward looking statements are based on Amplia Therapeutics Ltd's beliefs, opinions and estimates. No obligation is assumed to update forward looking statements if these beliefs, opinions and estimates should change or to reflect other future developments.

News Coverage

Current news mentioning Amplia Therapeutics Ltd from top publishers around the web.

Crucible: Dr Boreham’s A-To-Z of 2024 biotech

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of...

Read Article

Tackling significant unmet needs in cancer and fibrosis

Company

Website

Sector

Industry

Code

Socials

Company Overview

The Right Assets, The Right People And The Right Investors At The Right Time.

Investors

Timing & Expertise

Unmet Need

ASX presentation

The right opportunity...

...being tackled by the right assets...

...being managed by the right people...

Warwick Tong MB ChB MPP GAICD

John Lambert PhD GAICD

Robert Peach PhD

Christopher Burns BSc (Hons) PhD GAICD

....and supported by the right investors...

Substantial Shareholder

... at the right time.

News Coverage

Crucible: Dr Boreham’s A-To-Z of 2024 biotech

Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?

ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns

October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’

Closing Bell: ASX slumps as Woolies fires warning; graphite stock GCM’s shares triple on new deal

Health Check: Rats – and investors – are happy as Nyrada forges ahead with its first human brain injury trial

Amplia CEO co-recipient of 2024 Prime Minister’s Prize for Innovation

September Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut

Morning Brief: Key Insights Ahead of the ASX Opening

Closing Bell: ASX takes breather, goldies shine, Woolies and Coles charged over sneaky discounts

Stocks of the Hour: Amplia Therapeutics, Wellard, Anax Metals

Closing Bell: Most ASX sectors flash green on another record day; Mithril strikes gold in Mexico

Amplia Therapeutics allocated FDA fast-tracking for pancreatic cancer drug narmafotinib

Top 10 at 11: Silver takes the lead, but a cancer-drug competitor is also running hard

Market Highlights: Nasdaq soars and S&P 500 hits record; Ellison climbs rich ladder on Oracle’s AI plans

MoneyTalks: Pengana’s James McDonald reveals his top three ASX biotechs

August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’

Dr Boreham’s Crucible: Diverse ASX biotech gun Telix brushes off suggestions its peaked

ATX ASX | Amplia Therapeutics Ltd | Market Insights, News

ASX Market Close: Index up again, Min Res gains on job loss plan | August 7, 2024

Amplia moves to next stage of cancer drug trial for narmafotinib

July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month

Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners

Closing Bell: ASX axed in regional rout while mini-biotech Tissue Repair soars on TGA nod

2 ASX biotech shares rocketing more than 40% on big news

Investors’ sneak peek at biotech’s bright future

ASX Health Stocks: Island to tackle deadly Ebola virus

Amplia enrols new patients to progress testing for pancreatic cancer drug

ASX Health June Winners: Actinogen and Optiscan led a sector in good shape

The ASX biotechs with secured FDA clearances in 2024, and others looking likely

Dr Boreham’s Crucible: Amplia Therapeutics

ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year

Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

Amplia Therapeutics updates on next stage of ACCENT pancreatic cancer trial

Amplia Therapeutics takes step up in pancreatic cancer treatment

Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

ASX Health Stocks: Amplia’s pancreatic cancer trial gets boost; Emyria’s MDMA therapy is one step closer

Amplia Therapeutics mints $2.4m R&D tax benefit

Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

AACR OVARIAN CANCER CONFERENCE PRESENTATION

Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

ASX cancer stocks guide: Here’s everything you need to know

Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Check Up: Australian biotech sector continues to be a magnet for US investors

Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

Dr Boreham’s Crucible: Telix Pharmaceuticals

Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

ASX Health Stocks: Tissue Repair and Radiopharm jump double digits after US FDA meetings

September Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut